Ge Li appointed Dr. Li Zhengqing, former global vice president of MSD, as CMO and President of R & D in Greater China

Hangzhou and Shaoxing, China March 1, 2019 -- Geli Pharmaceutical Co., Ltd (Geli pharmaceutical, 1672 HK), a R & D-driven innovation biotechnology company committed to solving the unmet medical needs in the three fields of antiviral, cancer and fatty liver disease, today announced that Dr Li Zhengqing was appointed chief medical officer and President of R & D in Greater China, and Wu jinzibo, founder, chairman and chief executive officer of Geli, was appointed Report Before joining Geli, Dr Li Zhengqing began to serve as global vice president and general manager of China R & D center in MSD in 2011 In his early years, he built MSD China into an integrated R & D organization with more than 600 employees Under his leadership, more than 20 products of MSD China have been approved successfully, of which more than 10 were approved in China from 2017 to 2018, including keytruda, zepatier, isentress, HPV vaccine (jiadaxiu and jiadaxiu 9), RotaTeq, bridion, NuvaRing and noxafil 。 "I'm very glad that Dr Li joined Geli at this critical moment," said Dr Wu "Geli's innovative drug research and release bureau is moving from China to the world Dr Li's past outstanding achievements, especially the successful research and development experience of the antiviral drugs sebeida, eisentine and the antitumor drug coreda, will bring great value and influence to Geli's future innovative drug research and development." "I'm impressed by Geli's R & D strategy and achievements in recent years," said Dr Li Zhengqing "I agree with Geli's vision of becoming a world-class top R & D driven innovation biotechnology company, and look forward to working with Dr Wu and team members to jointly develop new drugs around the world to meet the clinical needs of patients in China and even around the world." Dr Li has more than 20 years of new drug research and development experience, including 15 years of work experience in the United States and 8 years of work experience in China Prior to joining MSD China, Dr Li served as vice president and head of R & D center of Bristol Myers Squibb China from 2010 to 2011, and as executive director of global biometrics Department of Bristol Myers Squibb from 2006 to 2010 He has successfully developed and registered a variety of products while working for Pfizer and P & G pharmaceutical companies in the United States About Geli, a R & D driven innovation biotechnology company with two listed products, has been listed on the Hong Kong Stock Exchange (Geli pharmaceutical, 1672 HK) Geli's mission is to address the unmet medical needs in the three treatment areas of antiviral, cancer and fatty liver disease Under the leadership of a management team with profound professional knowledge and outstanding past achievements, Geli has developed into an integrated platform company, covering the entire value chain from new drug discovery and development to production and commercialization At present, Geli has two products on the market: the first direct antiviral drug for hepatitis C treatment developed by local enterprises in China, gonovi ® and the long-term interferon pegoxin ® with good market basis, which is used for hepatitis B and hepatitis C treatment in cooperation with Roche Geli's R & D pipeline includes antibody immunotherapy in different clinical development stages, the world's first or best of its kind small molecule drugs and siRNA drugs For more information, please visit our website: www.ascletis.com.cn Related reading: Geli and 3-V Biosciences have reached an agreement on cooperation and financing of non-alcoholic fatty hepatitis products Geli and Koning jieruida have become the strategic cooperation of PD-L1 antibody drugs in the field of viral diseases Geli and Roche sign the exclusive cooperation agreement on viral hepatitis drugs in China Ge Li, an innovative hepatitis C drug, entered Chengdu Medical Insurance